HU193359B - Process for preparing a delayed theophylline composition - Google Patents
Process for preparing a delayed theophylline composition Download PDFInfo
- Publication number
- HU193359B HU193359B HU854936A HU493685A HU193359B HU 193359 B HU193359 B HU 193359B HU 854936 A HU854936 A HU 854936A HU 493685 A HU493685 A HU 493685A HU 193359 B HU193359 B HU 193359B
- Authority
- HU
- Hungary
- Prior art keywords
- weight
- parts
- theophylline
- pellets
- particle size
- Prior art date
Links
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 title claims description 141
- 229960000278 theophylline Drugs 0.000 title claims description 70
- 239000000203 mixture Substances 0.000 title description 39
- 230000003111 delayed effect Effects 0.000 title description 2
- 238000004519 manufacturing process Methods 0.000 title description 2
- 239000008188 pellet Substances 0.000 claims description 59
- 239000011159 matrix material Substances 0.000 claims description 45
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 44
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 22
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 20
- 239000002245 particle Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 239000000725 suspension Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 10
- 239000001856 Ethyl cellulose Substances 0.000 claims description 10
- 229920001249 ethyl cellulose Polymers 0.000 claims description 10
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 6
- 239000004800 polyvinyl chloride Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims description 5
- 229920003086 cellulose ether Polymers 0.000 claims description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000002035 prolonged effect Effects 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 claims 1
- 239000001069 triethyl citrate Substances 0.000 claims 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 1
- 235000013769 triethyl citrate Nutrition 0.000 claims 1
- 229920003176 water-insoluble polymer Polymers 0.000 claims 1
- 229920003023 plastic Polymers 0.000 description 21
- 239000004033 plastic Substances 0.000 description 21
- 238000004090 dissolution Methods 0.000 description 17
- 238000009472 formulation Methods 0.000 description 15
- 239000012528 membrane Substances 0.000 description 15
- 239000008363 phosphate buffer Substances 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 230000006399 behavior Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000005507 spraying Methods 0.000 description 8
- 230000036765 blood level Effects 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 208000019116 sleep disease Diseases 0.000 description 4
- 208000022925 sleep disturbance Diseases 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000005243 fluidization Methods 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- -1 sorbitan fatty acid ester Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- ZSGNFZKQTZPONC-UHFFFAOYSA-N octyl octane-1-sulfonate Chemical class CCCCCCCCOS(=O)(=O)CCCCCCCC ZSGNFZKQTZPONC-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH611184 | 1984-12-21 | ||
| CH268385 | 1985-06-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUT40334A HUT40334A (en) | 1986-12-28 |
| HU193359B true HU193359B (en) | 1987-09-28 |
Family
ID=25691137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU854936A HU193359B (en) | 1984-12-21 | 1985-12-20 | Process for preparing a delayed theophylline composition |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US4803080A (show.php) |
| EP (1) | EP0185331B1 (show.php) |
| KR (1) | KR920006910B1 (show.php) |
| CN (1) | CN1008060B (show.php) |
| AU (1) | AU581274B2 (show.php) |
| BG (1) | BG60833B2 (show.php) |
| CA (1) | CA1261268A (show.php) |
| CS (1) | CS396391A3 (show.php) |
| DE (1) | DE3572924D1 (show.php) |
| DK (1) | DK164843C (show.php) |
| ES (1) | ES8704079A1 (show.php) |
| FI (1) | FI84782C (show.php) |
| GR (1) | GR853051B (show.php) |
| HU (1) | HU193359B (show.php) |
| IE (1) | IE58246B1 (show.php) |
| IL (1) | IL77322A (show.php) |
| NO (1) | NO171827C (show.php) |
| NZ (1) | NZ214534A (show.php) |
| PT (1) | PT81714B (show.php) |
| SK (1) | SK278868B6 (show.php) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4753945A (en) * | 1986-02-19 | 1988-06-28 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion with phosphodiesterase inhibitors |
| GB8628728D0 (en) * | 1986-12-02 | 1987-01-07 | Euro Celtique Sa | Spheroids |
| EP0327295A3 (en) * | 1988-02-01 | 1989-09-06 | F.H. FAULDING & CO. LTD. | Tetracycline dosage form |
| US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
| US5196203A (en) * | 1989-01-06 | 1993-03-23 | F. H. Faulding & Co. Limited | Theophylline dosage form |
| DE3929864A1 (de) * | 1989-09-08 | 1991-03-14 | Nordmark Arzneimittel Gmbh | Verfahren zur herstellung von theophyllin-pellets |
| GB2284761A (en) * | 1993-12-03 | 1995-06-21 | Euro Celtique Sa | Prophylactic treatment of asthma |
| AU2005325930B2 (en) * | 2005-01-27 | 2012-01-19 | Alembic Limited | Extended release formulation of Levetiracetam |
| US20080014271A1 (en) * | 2006-07-13 | 2008-01-17 | Ucb, S.A. | Novel pharmaceutical compositions comprising levetiracetam |
| MX2014000419A (es) | 2011-07-15 | 2014-09-22 | Nusirt Sciences Inc | Composicones y metodos para modular trayectorias metabolicas. |
| BR112015010947A2 (en) | 2012-11-13 | 2018-06-05 | Nusirt Sciences, Inc. | compositions and methods for increasing energy metabolism. |
| JP2016505023A (ja) | 2013-01-15 | 2016-02-18 | ニューサート サイエンシーズ， インコーポレイテッド | 肺の状態の処置 |
| SG11201507046UA (en) | 2013-03-15 | 2015-10-29 | Nusirt Sciences Inc | Leucine and nicotinic acid reduces lipid levels |
| CA2939833A1 (en) | 2014-02-27 | 2015-09-03 | Nusirt Sciences, Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
| JP6826730B2 (ja) * | 2015-04-16 | 2021-02-10 | 学校法人 関西大学 | 抗氷核活性剤 |
| CN106176682A (zh) * | 2016-08-30 | 2016-12-07 | 铜陵翔宇商贸有限公司 | 茶碱缓释制胶囊剂及其制备方法 |
| WO2020067887A1 (en) | 2018-09-24 | 2020-04-02 | Erasmus University Medical Center Rotterdam | Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses |
| GB202001237D0 (en) * | 2020-01-29 | 2020-03-11 | Sisteks D O O | Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1091289B (de) * | 1956-01-25 | 1960-10-20 | Hans Lowey | Verfahren zur Herstellung einer oral anzuwendenden Arzneiform mit verlaengerter Wirkungsdauer |
| DE2336218C3 (de) * | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
| US4587118A (en) * | 1981-07-15 | 1986-05-06 | Key Pharmaceuticals, Inc. | Dry sustained release theophylline oral formulation |
| WO1983000284A1 (en) * | 1981-07-15 | 1983-02-03 | Key Pharma | Sustained release theophylline |
| US4704284A (en) * | 1982-08-12 | 1987-11-03 | Pfizer Inc. | Long-acting matrix tablet formulations |
| IE55745B1 (en) * | 1983-04-06 | 1991-01-02 | Elan Corp Plc | Sustained absorption pharmaceutical composition |
| DE3435325A1 (de) * | 1983-04-09 | 1986-04-17 | Nikken Chemicals Co., Ltd., Tokio/Tokyo | Langzeitwirkende theophyllin-tablette und verfahren zu deren herstellung |
-
1985
- 1985-12-10 IE IE310785A patent/IE58246B1/en not_active IP Right Cessation
- 1985-12-12 NZ NZ214534A patent/NZ214534A/xx unknown
- 1985-12-13 EP EP85115942A patent/EP0185331B1/de not_active Expired
- 1985-12-13 IL IL77322A patent/IL77322A/xx not_active IP Right Cessation
- 1985-12-13 DE DE8585115942T patent/DE3572924D1/de not_active Expired
- 1985-12-16 FI FI854973A patent/FI84782C/fi not_active IP Right Cessation
- 1985-12-18 CA CA000497980A patent/CA1261268A/en not_active Expired
- 1985-12-18 GR GR853051A patent/GR853051B/el not_active IP Right Cessation
- 1985-12-19 PT PT81714A patent/PT81714B/pt unknown
- 1985-12-20 NO NO855215A patent/NO171827C/no not_active IP Right Cessation
- 1985-12-20 US US06/811,742 patent/US4803080A/en not_active Expired - Fee Related
- 1985-12-20 DK DK600485A patent/DK164843C/da not_active IP Right Cessation
- 1985-12-20 AU AU51618/85A patent/AU581274B2/en not_active Expired
- 1985-12-20 ES ES550291A patent/ES8704079A1/es not_active Expired
- 1985-12-20 HU HU854936A patent/HU193359B/hu unknown
- 1985-12-21 KR KR1019850009678A patent/KR920006910B1/ko not_active Expired
- 1985-12-21 CN CN85109688A patent/CN1008060B/zh not_active Expired
-
1991
- 1991-12-20 CS CS913963A patent/CS396391A3/cs unknown
- 1991-12-20 SK SK3963-91A patent/SK278868B6/sk unknown
-
1994
- 1994-02-28 BG BG098598A patent/BG60833B2/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL77322A (en) | 1990-07-12 |
| FI84782C (fi) | 1992-01-27 |
| DK164843C (da) | 1993-01-11 |
| FI854973A0 (fi) | 1985-12-16 |
| SK278868B6 (sk) | 1998-04-08 |
| PT81714B (pt) | 1988-04-21 |
| CA1261268A (en) | 1989-09-26 |
| US4803080A (en) | 1989-02-07 |
| NZ214534A (en) | 1988-08-30 |
| KR860004634A (ko) | 1986-07-11 |
| NO171827B (no) | 1993-02-01 |
| DK600485A (da) | 1986-06-22 |
| AU581274B2 (en) | 1989-02-16 |
| CS396391A3 (en) | 1992-06-17 |
| NO855215L (no) | 1986-06-23 |
| NO171827C (no) | 1993-05-12 |
| DE3572924D1 (en) | 1989-10-19 |
| DK600485D0 (da) | 1985-12-20 |
| IE58246B1 (en) | 1993-08-11 |
| ES8704079A1 (es) | 1987-04-01 |
| HUT40334A (en) | 1986-12-28 |
| KR920006910B1 (ko) | 1992-08-22 |
| PT81714A (de) | 1986-01-01 |
| CN85109688A (zh) | 1986-06-10 |
| CN1008060B (zh) | 1990-05-23 |
| EP0185331B1 (de) | 1989-09-13 |
| DK164843B (da) | 1992-08-31 |
| ES550291A0 (es) | 1987-04-01 |
| FI854973L (fi) | 1986-06-22 |
| AU5161885A (en) | 1986-07-17 |
| FI84782B (fi) | 1991-10-15 |
| GR853051B (show.php) | 1986-02-03 |
| EP0185331A1 (de) | 1986-06-25 |
| IE853107L (en) | 1986-06-21 |
| BG60833B2 (bg) | 1996-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3157190B2 (ja) | 薬剤のための味マスキング及び持効性皮膜 | |
| US5296236A (en) | Controlled release therapeutic system for a liquid pharmaceutical formulations | |
| CA2281420C (en) | Preparation of pharmaceutically-active granules | |
| US5576022A (en) | Controlled release tacrine drug delivery systems and methods for preparing same | |
| JP3258666B2 (ja) | 徐放性のブデゾナイドペレット及びその製造方法 | |
| US5876759A (en) | Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof | |
| US4851226A (en) | Chewable medicament tablet containing means for taste masking | |
| US5670171A (en) | Liquid-suspension controlled-release pharmaceutical composition | |
| CA1218305A (en) | Combination formulation | |
| US5122384A (en) | Oral once-per-day organic nitrate formulation which does not induce tolerance | |
| FI84782C (fi) | Foerfarande foer framstaellning av ett teofyllinpreparat med foerlaengd verkan. | |
| JP2599189B2 (ja) | 味覚遮蔽剤を含有している咀嚼可能な薬物錠剤 | |
| JP2000500477A (ja) | 即時放出型の薬学的組成物 | |
| JPH0245418A (ja) | 薬物顆粒並びに該顆粒から製造した錠剤 | |
| JP2719835B2 (ja) | 液状薬理製剤用制御放出治療システム | |
| US20060121114A1 (en) | Method of manufacturing sustained release microbeads containing venlafaxine HCL | |
| JPH0328404B2 (show.php) | ||
| WO2003043610A2 (en) | A process for manufacture of a sustained release composition containing microbe | |
| JPH01313431A (ja) | ジルチアゼム・マイクロビーズ、その製法および徐放性医薬組成物 | |
| KR100193121B1 (ko) | 맛 차폐 및 서방성 약제용 피복물 | |
| JPS61152629A (ja) | 徐放性テオフィリン調剤及びその製法 | |
| MXPA94005567A (en) | Controlled release systems for the pharmacotacrine and methods to prepare |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HU90 | Patent valid on 900628 | ||
| HPC4 | Succession in title of patentee |
Owner name: ALTANA PHARMA AG, DE |